Details of the Drug Reposition

General Information of This Drug (ID: DMAIGTE)

Drug Name
SurVaxM   DMAIGTE

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Glioblastoma of brain DISESTHB 2A00.00 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple myeloma DISEWP9B 2A83 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04013672) Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)